PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Paclitaxel|DRUG: AZD5363|DRUG: Placebo
Sponsor: Queen Mary University of London
Collaborators: AstraZeneca|Cancer Research UK